fda warning letters compounding semaglutide september 2025 Warns Novo Nordisk on Unreported Deaths US FDA sends 25 letters

These references include clinical trials, academic papers, and expert sources that have been pivotal in exploring the relationship between semaglutide and kidney stones, as well as the broader context of kidney health and diabetes management

PMID 25485164

Nat Med (2018) 24:90822

Compounded semaglutide injections require precise storage conditions to maintain their chemical stability and therapeutic effectiveness

The debate on the enduring impact of these drugs in the relentlessly evolving landscape will and should continue

Various alternatives and considerations When initiating oral glucose-lowering monotherapy, medication adjustments should be made every 23 months based on HbA1c levels